Innoviva, Inc. (INVA) stock
INVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3040% below fair value
$19.03+0.06 (+0.32%)
Close on Nov 13, 2026Market cap $1.37BP/E 9.7Yield –
Innoviva EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Innoviva's EPS for the twelve months ending Sep 30, 2026 was $1.97. For fiscal 2025 it was $3.30, up 816.7% from the year before. The highest annual figure on record is $3.53 in fiscal 2018.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.30 | +816.7% |
| FY2024 | Dec 31, 2024 | $0.36 | -83.6% |
| FY2023 | Dec 31, 2023 | $2.20 | -7.2% |
| FY2022 | Dec 31, 2022 | $2.37 | -17.4% |
| FY2021 | Dec 31, 2021 | $2.87 | +42.1% |
| FY2020 | Dec 31, 2020 | $2.02 | +41.3% |
| FY2019 | Dec 31, 2019 | $1.43 | -59.5% |
| FY2018 | Dec 31, 2018 | $3.53 | +201.7% |
| FY2017 | Dec 31, 2017 | $1.17 | +120.8% |
| FY2016 | Dec 31, 2016 | $0.53 | – |
| FY2015 | Dec 31, 2015 | -$0.16 | – |
| FY2014 | Dec 31, 2014 | -$1.50 | – |
| FY2013 | Dec 31, 2013 | -$1.67 | – |
| FY2012 | Dec 31, 2012 | -$0.20 | – |
| FY2011 | Dec 31, 2011 | -$1.41 | – |
| FY2010 | Dec 31, 2010 | -$1.16 | – |
| FY2009 | Dec 31, 2009 | -$1.35 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$1.03 | -195.4% |
| Q2 FY2026 | Jun 30, 2026 | -$1.14 | -248.1% |
| Q1 FY2026 | Mar 31, 2026 | $2.22 | – |
| Q4 FY2025 | Dec 31, 2025 | $1.92 | +9500.0% |
| Q3 FY2025 | Sep 30, 2025 | $1.08 | – |
| Q2 FY2025 | Jun 30, 2025 | $0.77 | +67.4% |
| Q1 FY2025 | Mar 31, 2025 | -$0.74 | -202.8% |
| Q3 FY2024 | Sep 30, 2024 | $0.02 | -98.0% |
| Q2 FY2024 | Jun 30, 2024 | -$0.55 | -2850.0% |
| Q1 FY2024 | Mar 31, 2024 | $0.46 | +9.5% |
| Q4 FY2023 | Dec 31, 2023 | $0.72 | – |
| Q3 FY2023 | Sep 30, 2023 | $0.98 | -65.0% |
| Q2 FY2023 | Jun 30, 2023 | $0.02 | -60.0% |
| Q1 FY2023 | Mar 31, 2023 | $0.42 | +110.0% |
| Q4 FY2022 | Dec 31, 2022 | -$0.71 | -646.2% |
| Q3 FY2022 | Sep 30, 2022 | $2.80 | +211.1% |
| Q2 FY2022 | Jun 30, 2022 | $0.05 | -94.4% |
| Q1 FY2022 | Mar 31, 2022 | $0.20 | -76.2% |
| Q4 FY2021 | Dec 31, 2021 | $0.13 | -72.3% |
| Q3 FY2021 | Sep 30, 2021 | $0.90 | +246.2% |
| Q2 FY2021 | Jun 30, 2021 | $0.90 | +30.4% |
| Q1 FY2021 | Mar 31, 2021 | $0.84 | +42.4% |
| Q4 FY2020 | Dec 31, 2020 | $0.47 | +11.9% |
| Q3 FY2020 | Sep 30, 2020 | $0.26 | -27.8% |
| Q2 FY2020 | Jun 30, 2020 | $0.69 | +102.9% |
| Q1 FY2020 | Mar 31, 2020 | $0.59 | +90.3% |
| Q4 FY2019 | Dec 31, 2019 | $0.42 | -82.1% |
| Q3 FY2019 | Sep 30, 2019 | $0.36 | -16.3% |
| Q2 FY2019 | Jun 30, 2019 | $0.34 | -30.6% |
| Q1 FY2019 | Mar 31, 2019 | $0.31 | +14.8% |
| Q4 FY2018 | Dec 31, 2018 | $2.34 | +368.0% |
| Q3 FY2018 | Sep 30, 2018 | $0.43 | +104.8% |
| Q2 FY2018 | Jun 30, 2018 | $0.49 | +63.3% |
| Q1 FY2018 | Mar 31, 2018 | $0.27 | +80.0% |
| Q4 FY2017 | Dec 31, 2017 | $0.50 | +127.3% |
| Q3 FY2017 | Sep 30, 2017 | $0.21 | – |
| Q2 FY2017 | Jun 30, 2017 | $0.30 | – |
| Q1 FY2017 | Mar 31, 2017 | $0.15 | – |
| Q4 FY2016 | Dec 31, 2016 | $0.22 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?